title: Transferrin-conjugated polymeric nanomedicine to enhance the anticancer efficacy of edelfosine in acute myeloid leukemia.
abstract: In this study, transferrin (Tf)-conjugated polyethylene glycol (PEG)-poly-l-lysine (PLL)-poly(lactic-co-glycolic acid) (PLGA) (PEG-PLL-PLGA)-based micellar formulations were successfully prepared for the delivery of edelfosine (EDS) in leukemia treatment. The micelles were nanosized and presented spherical shaped particles. Our in vitro data suggest that the nanoformulations maintain the biological activity of drugs for longer periods and lead to a continuous release of active drug. The enhanced cellular uptake of EDS-TM resulted in significantly higher cytotoxic effect in K562 leukemia cells. Cell cycle analysis further demonstrated the significantly higher G2/M phase arrest of cancer cells. Immunoblot analysis clearly revealed the potential of EDS-TM in inducing apoptosis of cancer cells which could improve the anticancer efficacy in leukemia. Importantly, EDS-M and EDS-TM significantly prolonged the circulation profile of EDS throughout until 24h, indicating the potential of targeted nanoparticulate delivery system. The prolonged blood circulation potential of micellar formulations might improve the therapeutic potential of drug by increasing its bioavailability in the serum. It would be worthwhile evaluating the effects of the EDS-loaded micelles on cancer cells in vivo for clinical application.
authors.affiliation: Nanchang University, The First Clinical Medical College, Nanchang, Jiangxi, 330006, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Nanchang University, The First Clinical Medical College, Nanchang, Jiangxi, 330006, China; Department of Hematology, Shandong Jining No. 1 People's Hospital, Shandong, 272011, China. Electronic address: sunzhongliang431@hotmail.com.
authors.forename: Zhong-Liang
authors.initials: ZL
authors.lastname: Sun
mesh_terms: D061605:Administration, Intravenous; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D065546:Drug Liberation; D000067493:Dynamic Light Scattering; D006801:Humans; D015151:Immunoblotting; D020014:K562 Cells; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008823:Micelles; D050997:Nanomedicine / Q000379:methods*; D010742:Phospholipid Ethers / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011108:Polymers / Q000138:chemical synthesis / Q000737:chemistry*; D014168:Transferrin / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D008823:Micelles; D010742:Phospholipid Ethers; D011108:Polymers; D014168:Transferrin; C026659:edelfosine
keywords: Anticancer efficacy; Apoptosis; Edelfosine; Leukemia; Micelles